Allison Bratzel
Stock Analyst at Piper Sandler
(4.73)
# 156
Out of 5,006 analysts
42
Total ratings
75.76%
Success rate
19.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $39.80 | +28.14% | 4 | Sep 24, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $750 → $820 | $787.94 | +4.07% | 14 | Aug 26, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $65 | $69.02 | -5.82% | 2 | Aug 22, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $86.67 | +29.23% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $4.68 | +370.09% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $13.43 | +145.72% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $30.19 | +280.92% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $2.97 | +102.02% | 1 | Mar 14, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $7.63 | +240.76% | 1 | Feb 18, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $26.13 | -15.81% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $28.90 | -20.42% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $16.26 | +35.30% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $2.48 | +61.29% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.48 | +264.96% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $5.87 | +240.72% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $87.23 | +14.64% | 2 | Feb 8, 2023 |
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $39.80
Upside: +28.14%
argenx SE
Aug 26, 2025
Maintains: Overweight
Price Target: $750 → $820
Current: $787.94
Upside: +4.07%
Ionis Pharmaceuticals
Aug 22, 2025
Maintains: Overweight
Price Target: $62 → $65
Current: $69.02
Upside: -5.82%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $86.67
Upside: +29.23%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $4.68
Upside: +370.09%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $13.43
Upside: +145.72%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $30.19
Upside: +280.92%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $2.97
Upside: +102.02%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $7.63
Upside: +240.76%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $26.13
Upside: -15.81%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $28.90
Upside: -20.42%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $16.26
Upside: +35.30%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $2.48
Upside: +61.29%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.48
Upside: +264.96%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $5.87
Upside: +240.72%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $87.23
Upside: +14.64%